GLP‑1 obesity drugs associated with lower daily activity in patients

Research presented at the ENDO 2026 conference shows that adults with obesity who start GLP‑1 receptor agonist therapy—such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound)—take fewer steps and spend less time in moderate‑to‑vigorous exercise. In a analysis of 753 participants from the All of Us Research Program (average age 52.7, 78.6% women), daily steps fell from about 5,047 to 4,487 after treatment began, and daily MVPA minutes dropped from 28 to 22. The decline was most pronounced among men and those reporting joint or muscle pain, raising concerns that weight loss may not automatically increase physical activity and could affect muscle mass.

Separately, a German broadcast scheduled for 18 June will host experts to answer public questions about GLP‑1 “weight‑loss injections,” covering how the drugs work, who can use them, potential side effects, the role of diet, and alternatives after discontinuation. The program aims to inform viewers about both the benefits and risks of these increasingly popular obesity treatments.